Natural Product (NP) Details
| General Information of the NP (ID: NP7102) | |||||
|---|---|---|---|---|---|
| Name |
Elemene
|
||||
| Synonyms |
Cyclohexane, 1-ethenyl-1-methyl-2,4-bis(1-methylethenyl)-, (1R,2R,4S)-rel-; 33880-83-0; beta-Elemene, (-)-; (- )-bete-elemene; EINECS 251-713-0; AC1L1VID; Cyclohexane, 2,4-diisopropenyl-1-methyl-1-vinyl-, (1S,2S,4R)-; OPFTUNCRGUEPRZ-UHFFFAOYSA-N; Cyclohexane, 1-ethenyl-1-methyl-2,4-bis(1-methylethenyl)-, (1S-(1-alpha,2-beta,4-beta))-; (1alpha,2beta,4beta)-1-Methyl-2,4-bis(methylvinyl)-1-vinylcyclohexane; LS-56795; EN300-296339; 1-Methyl-1-vinyl-2,4-diisopropenylcyclohexane
Click to Show/Hide
|
||||
| Species Origin | Pogostemon cablin ... | Click to Show/Hide | |||
| Pogostemon cablin | |||||
| Atractylodes lancea | |||||
| Abutilon indicum | |||||
| Disease | Solid tumour/cancer [ICD-11: 2A00-2F9Z] | Phase 1 | [1] | ||
| Structure |
|
Click to Download Mol2D MOL |
|||
| Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product | |||||
| Formula |
C15H24
|
||||
| PubChem CID | |||||
| Canonical SMILES |
CC(=C)C1CCC(C(C1)C(=C)C)(C)C=C
|
||||
| InChI |
1S/C15H24/c1-7-15(6)9-8-13(11(2)3)10-14(15)12(4)5/h7,13-14H,1-2,4,8-10H2,3,5-6H3/t13-,14+,15-/m1/s1
|
||||
| InChIKey |
OPFTUNCRGUEPRZ-QLFBSQMISA-N
|
||||
| CAS Number |
CAS 33880-83-0
|
||||
| Herb ID | |||||
| ETMC ID | |||||
| SymMap ID | |||||
| TTD Drug ID | |||||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. A List of Drug(s) Whose Efficacy can be Enhanced by This NP | ||||||
| Cisplatin | Bladder cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
| Augmenting Drug Sensitivity | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [2] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Up-regulation | Expression | BAX | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | BCL-2 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Cleavage | CASP3 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Cleavage | CASP7 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Cleavage | CASP9 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | XIAP | Molecule Info |
Pathway MAP
|
||
| Biological
Regulation |
Up-regulation | Cytochrome c release | ||||
| In-vitro Model | A-549 | CVCL_0023 | Lung adenocarcinoma | Homo sapiens | ||
| NCI-H460 | CVCL_0459 | Lung large cell carcinoma | Homo sapiens | |||
| Experimental
Result(s) |
beta-Elemene increases cisplatin chemosensitivity of lung tumor cells by triggering apoptosis. | |||||
| Temozolomide | Brain cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [3] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Down-regulation | Expression | AKT1 | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Phosphorylation | ATM | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | ERK1 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | H2AFX | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | U-87MG ATCC | CVCL_0022 | Glioblastoma | Homo sapiens | ||
| T98G | CVCL_0556 | Glioblastoma | Homo sapiens | |||
| U-251MG | CVCL_0021 | Astrocytoma | Homo sapiens | |||
| LN-229 | CVCL_0393 | Glioblastoma | Homo sapiens | |||
| C6 | CVCL_0194 | Rat malignant glioma | Rattus norvegicus | |||
| Experimental
Result(s) |
Beta-elemene enhances both radiosensitivity and chemosensitivity of glioblastoma cells through the inhibition of the ATM signaling pathway. | |||||
| Cetuximab | Colorectal cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [4] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Down-regulation | Expression | CDH1 | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Expression | CDH1 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | CDH2 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | GLS2 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | GPX4 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | HMOX1 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | HMOX1 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | MMP-9 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | SLC40A1 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | SLC7A11 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | SNAI1 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | SNAI2 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | TF | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | TF | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | VIM | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | HCT 116 | CVCL_0291 | Colon carcinoma | Homo sapiens | ||
| In-vivo Model | A volume of 100 ul HCT116-luc cells suspension (2.5*106 cells/ml) was injected subcutaneously into right dorsal flank of mice (5-week-old female BALB/c nude mice). | |||||
| Experimental
Result(s) |
Combinative treatment of Beta-elemene and cetuximab is sensitive to KRAS mutant colorectal cancer cells by inducing ferroptosis and inhibiting epithelial-mesenchymal transformation. | |||||
| DC/Dribble vaccine | Lung cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [5] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Up-regulation | Expression | IFNG | Molecule Info |
Pathway MAP
|
|
| In-vitro Model | BNL1MEA.7R.1 | Hepatocellular carcinoma | Rattus norvegicus | |||
| Experimental
Result(s) |
Beta-elemene combined DC/Dribble vaccine could induce specific immune cells to secrete secretory cells, thus exerting its anti-tumor effect. | |||||
| Gefitinib | Lung cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [6] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Up-regulation | Expression | CDH1 | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | CDH2 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | HES1 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | MYC | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | NOTCH1 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | SHH | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | SNAI1 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | SOX2 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | TWIST1 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | VIM | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | ZEB1 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | A-549 | CVCL_0023 | Lung adenocarcinoma | Homo sapiens | ||
| NCI-H1299 | CVCL_0060 | Lung large cell carcinoma | Homo sapiens | |||
| Experimental
Result(s) |
Beta-Elemene synergizes with gefitinib to inhibit stem-like phenotypes and progression of lung cancer via down-regulating EZH2. | |||||
| TNF-related apoptosis inducing ligand | Lung cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [7] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Up-regulation | Expression | CASP3 | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Expression | CASP8 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | FADD | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | PARP1 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | TRAIL-R2 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | BGC-823 | CVCL_3360 | Gastric cancer | Homo sapiens | ||
| SGC-7901 | CVCL_0520 | Human gastric cancer | Homo sapiens | |||
| Experimental
Result(s) |
Beta-elemene increases the sensitivity of gastric cancer cells to TRAIL by promoting the formation of DISC in lipid rafts. | |||||
| Rapamycin | Multiple myeloma | Click to Show/Hide the Molecular Data of This Drug | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [8] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Down-regulation | Phosphorylation | AKT1 | Molecule Info |
Pathway MAP
|
|
| In-vitro Model | FTC-133 | CVCL_1219 | Thyroid gland follicular carcinoma | Homo sapiens | ||
| Experimental
Result(s) |
The novel combination of mTOR inhibitor with Beta-elemene synergistically attenuates tumor cell growth in follicular thyroid cancer, which requires additional preclinical validation. | |||||
| 5-fluorouracil | Solid tumour/cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [9] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Down-regulation | Phosphorylation | AKT1 | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Phosphorylation | c-RAF | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Phosphorylation | CYB5R2 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Phosphorylation | ERK1 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | PIK3R1 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | BT-549 | CVCL_1092 | Invasive breast carcinoma | Homo sapiens | ||
| MDA-MB-231 | CVCL_0062 | Breast adenocarcinoma | Homo sapiens | |||
| In-vivo Model | MDA-MB-231 cells (5*106 cells in 100 uL of PBS) were subcutaneously injected to the left flank of femal nude mice. | |||||
| Experimental
Result(s) |
Beta-Elemene enhances the chemotherapeutic effect of 5-Fluorouracil in triple-negative breast cancer via PI3K/AKT, RAF-MEK-ErK, and NF-KappaB signaling pathways. | |||||
| Etoposide | Testicular carcinoma | Click to Show/Hide the Molecular Data of This Drug | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [10] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Up-regulation | Expression | BAX | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | CCND1 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | CDKN1A | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Cleavage | PARP1 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | TP53 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | A-549 | CVCL_0023 | Lung adenocarcinoma | Homo sapiens | ||
| Experimental
Result(s) |
Synergistic antitumor effect of Beta-elemene and etoposide is mediated via induction of cell apoptosis and cell cycle arrest in non-small cell lung carcinoma cells. | |||||
| β. A List of Drug(s) Whose Resistance can be Reversed by This NP | ||||||
| Oxaliplatin | Colorectal cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
| Reversing Drug Resistance | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [11] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Down-regulation | Phosphorylation | AKT1 | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Expression | BECN1 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Cleavage | CASP3 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Phosphorylation | ERK1 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | MAP1LC3A | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Cleavage | PAEP | Molecule Info | |||
| In-vitro Model | MHCC97-H | CVCL_4972 | Adult hepatocellular carcinoma | Homo sapiens | ||
| HCCLM3 | CVCL_6832 | Adult hepatocellular carcinoma | Homo sapiens | |||
| In-vivo Model | Human HCC cell line MHCC97H were used to estabolish xenograft models in the BALB/c mice. | |||||
| Experimental
Result(s) |
Beta-elemene sensitizes hepatocellular carcinoma cells to oxaliplatin by preventing oxaliplatin-induced degradation of copper transporter 1. | |||||
